Jyong Biotech Ltd.
No SEC Form 4 filings for $MENS in the last 30 days.
See all $MENS insider activity →Jyong Biotech (MENS) plans a U.S. manufacturing facility in Texas to support potential commercialization of its investigational drugs, focusing on BPH/LUTS market. The facility is subject to regulatory approval and funding. MENS shares were unchanged at $2.05.
New Taipei City, Taiwan, Nov. 24, 2025 ( GLOBE NEWSWIRE ) -- Jyong Biotech Ltd. ( Nasdaq: MENS ) ( the "Company" or "Jyong Biotech" ) , a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs ( plant-derived ) ...
New Taipei City, Taiwan, Nov. 20, 2025 ( GLOBE NEWSWIRE ) -- Jyong Biotech Ltd. ( Nasdaq: MENS ) ( the "Company" or "Jyong Biotech" ) , a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs ( plant-derived ) ...
Over the past 7 days, AlphAI's AI scored 1 news story mentioning MENS (Jyong Biotech Ltd.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
The announcement adds a modest, long‑term growth catalyst but no immediate financial impact.
The announcement of a non-binding licensing agreement by Jyong Biotech indicates ongoing industry activity in plant-derived drugs, potentially positive for biotech stocks, including MENS.
Positive clinical trial results for MCS-8 suggest potential for stock appreciation.
The company's leadership presence at an international event could enhance its visibility and credibility, potentially supporting its stock price in the short to medium term.
The completion of patient enrollment in Jyong Biotech's Phase II trial indicates progress in its drug development pipeline, potentially leading to future product approval and revenue streams.
AlphAI scores every news story that mentions MENS with an AI model for sentiment and relevance, and aggregates insider trades from Jyong Biotech Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Jyong Biotech (MENS) plans a U.S. manufacturing facility in Texas to support potential commercialization of its investigational drugs, focusing on BPH/LUTS market. The facility is subject to regulatory approval and funding. MENS shares were unchanged at $2.05.
1 min readNew Taipei City, Taiwan, Nov. 24, 2025 ( GLOBE NEWSWIRE ) -- Jyong Biotech Ltd. ( Nasdaq: MENS ) ( the "Company" or "Jyong Biotech" ) , a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs ( plant-derived ) ...
2 min readNew Taipei City, Taiwan, Nov. 20, 2025 ( GLOBE NEWSWIRE ) -- Jyong Biotech Ltd. ( Nasdaq: MENS ) ( the "Company" or "Jyong Biotech" ) , a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs ( plant-derived ) ...
2 min readNew Taipei City, Taiwan, Sept. 18, 2025 ( GLOBE NEWSWIRE ) -- Jyong Biotech Ltd. ( Nasdaq: MENS ) ( the "Company", "Jyong Biotech" ) , a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs ( plant-derived ) ...
2 min readNew Taipei City, Taiwan, Sept. 16, 2025 ( GLOBE NEWSWIRE ) -- Jyong Biotech Ltd. ( Nasdaq: MENS ) ( the "Company", "Jyong Biotech" ) , a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs ( plant-derived ) ...
3 min readNew Taipei City, Taiwan, Aug. 22, 2025 ( GLOBE NEWSWIRE ) -- Jyong Biotech Ltd. ( Nasdaq: MENS ) ( the "Company", "Jyong Biotech" ) , a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs ( plant-derived ) ...
3 min readNew Taipei City, Taiwan, July 22, 2025 ( GLOBE NEWSWIRE ) -- Jyong Biotech Ltd. ( Nasdaq: MENS ) ( the "Company", "Jyong Biotech" ) , a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs ( plant-derived ) ...
2 min read
